Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis

  • Seyed Mohammad Baghbanian Bualicina Hospital, Mazandaran University of Medical sciences, Sari, Iran
  • Mohammad Ali Sahraian Multiple Sclerosis Research Centre, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
Keywords: Interferon-Beta, Glatiramer Acetate, Autoimmune Disease, Multiple Sclerosis

Abstract

Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly-used drugs as well. Induction or aggravation of other immune-mediated diseases has been reported following INF-β administration. We have reviewed the reported cases to notify the treating physicians about these rare adverse events. Although co-morbid autoimmune disorders have been reported in patients with MS, the pro-inflammatory role of disease-modifying drugs, especially INF-β, could affect and enhance this co-occurrence. Clinical or laboratory autoimmunity histories suggest the use of GA over INF-β as the treatment of choice.

References

1. Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168(2): 96-106.
2. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis: A geographically based study 10: relapses and long-term disability. Brain 2010; 133(Pt 7): 1914-29.
3. Bordi I, Umeton R, Ricigliano VA, Annibali V, Mechelli R, Ristori G, et al. A mechanistic, stochastic model helps understand multiple sclerosis course and pathogenesis. Int J Genomics 2013; 2013: 910321.
4. Koch-Henriksen N. The Danish Multiple Sclerosis Registry: A 50-year follow-up. Mult Scler 1999; 5(4): 293-6.
5. Annibali V, Mechelli R, Romano S, Buscarinu MC, Fornasiero A, Umeton R, et al. IFN-beta and multiple sclerosis: From etiology to therapy and back. Cytokine Growth Factor Rev 2015; 26(2): 221-8.
6. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147(927): 258-67.
7. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971; 1(4): 242-8.
8. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49(3): 290-7.
9. Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013; 12(5): 543-53.
10. McGraw CA, Lublin FD. Interferon beta and glatiramer acetate therapy. Neurotherapeutics 2013; 10(1): 2-18.
11. Strueby L, Nair B, Kirk A, Taylor-Gjevre RM. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta. Scand J Rheumatol 2005; 34(6): 485-8.
12. Altintas A, Alici Y, Melikoglu M, Siva A. Arthritis during interferon beta-1b treatment in multiple sclerosis. Mult Scler 2002; 8(6): 534-6.
13. Zheng B, Switzer K, Marinova E, Zhang J, Han S. Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production. Autoimmunity 2008; 41(5): 363-71.
14. Bonaci-Nikolic B, Jeremic I, Andrejevic S, Sefik-Bukilica M, Stojsavljevic N, Drulovic J. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis. Lupus 2009; 18(1): 78-80.
15. Nousari HC, Kimyai-Asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998; 352(9143): 1825-6.
16. Gono T, Matsuda M, Shimojima Y, Kaneko K, Murata H, Ikeda S. Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient. J Clin Neurosci 2007; 14(10): 997-1000.
17. Arrue I, Saiz A, Ortiz-Romero PL, Rodriguez-Peralto JL. Lupus-like reaction to interferon at the injection site: report of five cases. J Cutan Pathol 2007; 34(Suppl 1): 18-21.
18. Bahri DM, Khiari H, Essouri A, Laadhar L, Zaraa I, Mrabet A, et al. Systemic lupus erythematosus induced by interferon beta1 therapy in a patient with multiple sclerosis. Fundam Clin Pharmacol 2012; 26(2): 210-1.
19. Fellner A, Dano M, Regev K, Mosek A, Karni A. Multiple sclerosis is associated with psoriasis. A case-control study. J Neurol Sci 2014; 338(1-2): 226-8.
20. La ML, Capsoni F. Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci 2010; 31(3): 337-9.
21. Webster GF, Knobler RL, Lublin FD, Kramer EM, Hochman LR. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996; 34(2 Pt 2): 365-7.
22. Munschauer FE3rd, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997; 19(5): 883-93.
23. Samson M, Audia S, Duchene C, Perinet I, Bielefeld P, Besancenot JF. Crohn's disease during the course of multiple sclerosis: role of interferon-beta therapy. Rev Med Interne 2009; 30(9): 816-9. [In French].
24. Schott E, Paul F, Wuerfel JT, Zipp F, Rudolph B, Wiedenmann B, et al. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J Gastroenterol 2007; 13(26): 3638-40.
25. Rodrigues S, Magro F, Soares J, Nunes AC, Lopes S, Marques M, et al. Case series: ulcerative colitis, multiple sclerosis, and interferon-beta 1a. Inflamm Bowel Dis 2010; 16(12): 2001-3.
26. Tuna Y, Basar O, Dikici H, Koklu S. Rapid onset of ulcerative colitis after treatment with interferon beta1a in a patient with multiple sclerosis. J Crohns Colitis 2011; 5(1): 75-6.
27. Fernandez-Salazar L, Alvarez-Quinones M, Gonzalez Hernandez JM, Fraile A, Mayor E, Arranz E, et al. IFN beta 1b induced celiac disease. Scand J Gastroenterol 2011; 46(12): 1525-6.
28. Charach G, Grosskopf I, Weintraub M. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone. Digestion 2008; 77(3-4): 198-200.
29. Chakravarty SD, Harris ME, Schreiner AM, Crow MK. Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review. Semin Arthritis Rheum 2012; 42(2): 206-12.
30. Petousi N, Thomas EC. Interferon-beta-induced pulmonary sarcoidosis in a 30-year-old woman treated for multiple sclerosis: A case report. J Med Case Rep 2012; 6: 344.
31. Sahraian MA, Moghadasi AN, Owji M, Maboudi M, Kosari F, McGee JC, et al. Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: A case report. J Med Case Rep 2013; 7: 270.
32. Laird PW, Newman NJ, Yeh S. Exacerbation of Susac syndrome retinopathy by interferon Beta-1a. Arch Ophthalmol 2012; 130(6): 804-6.
33. Kumar N, Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler 2004; 10(1): 85-6.
34. Somani AK, Swick AR, Cooper KD, McCormick TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008; 144(10): 1341-9.
35. Trostle DC, Helfrich D, Medsger TA, Jr. Systemic sclerosis (scleroderma) and multiple sclerosis. Arthritis Rheum 1986; 29(1): 124-7.
36. Igarashi A, Imakado S, Ishibashi Y, Takehara K. Systemic sclerosis associated with multiple sclerosis. Arch Dermatol 1989; 125(8): 1145.
37. Jawad SH, Askari A, Ward AB. Case history of a patient with multiple sclerosis and scleroderma. Br J Rheumatol 1997;
36(4): 502-3.
38. Spadaro A, Sensi F, Barrella M, Francia A. Systemic sclerosis and multiple sclerosis. J Neurol 1999; 246(6): 497-9.
39. Chroni E, Paschalis C, Stergiou T, Vlahanastasi C, Andonopoulos AP. Multiple sclerosis in the course of systemic sclerosis. Ann Rheum Dis 2002; 61(2): 188.
40. Gorodkin R, Leahy B, Neary D, Herrick AL. Coexistence of systemic sclerosis and multiple sclerosis. J Neurol 2004; 251(12): 1524-5.
41. Pelidou SH, Tsifetaki N, Giannopoulos S, Deretzi G, Voulgari P, Kyritsis A. Multiple sclerosis associated with systemic sclerosis. Rheumatol Int 2007; 27(8): 771-3.
42. Airo' P, Scarsi M, Rossi M, Mondini M. Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis. Rheumatol Int 2008; 28(7): 703-7.
43. Kocer B, Nazliel B, Oztas M, Batur HZ. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: A case report. Eur J Neurol 2009; 16(4): e78-e79.
44. Cicek D, Kandi B, Oguz S, Cobanoglu B, Bulut S, Saral Y. An urticarial vasculitis case induced by glatiramer acetate. J Dermatolog Treat 2008; 19(5): 305-7.
45. Cortellini G, Amadori A, Comandini T, Corvetta A. Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin tests. Eur Ann Allergy Clin Immunol 2013; 45(5): 181-2.
46. Corominas M, Postigo I, Cardona V, Lleonart R, Romero-Pinel L, Martinez J. IgE-mediated allergic reactions after the first administration of glatiramer acetate in patients with multiple sclerosis. Int Arch Allergy Immunol 2014; 165(4): 244-6.
47. Kowalec K, Yoshida EM, Traboulsee A, Carleton B, Tremlett H. Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. Mult Scler Relat Disord 2013; 2(1): 57-9.
48. Villamil A, Mullen E, Casciato P, Gadano A. Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature. Ann Hepatol 2015; 14(2): 273-80.
49. Neumann H, Csepregi A, Sailer M, Malfertheiner P. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis. J Neurol 2007; 254(6): 816-7.
50. von K, V, Lohse AW, Schramm C. Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis--not only beta interferon. Am J Gastroenterol 2008; 103(8): 2147-8.
51. Alanoglu G, Kilbas S, Arslan C, Senol A, Kutluhan S. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis. Mult Scler 2007; 13(5): 683-5.
52. Saeedi M, Forughipour M, Sasannezhad P, Shoeibi A. Interferon-beta-1b induced autoimmune hemolytic anemia in a patient with MS: A case report. Iran Red Crescent Med J 2011; 13(3): 210-2.
53. Olea T, Diaz-Mancebo R, Picazo ML, Martinez-Ara J, Robles A, Selgas R. Thrombotic microangiopathy associated with use of interferon-beta. Int J Nephrol Renovasc Dis 2012; 5: 97-100.
54. Milan MS, Virzi GM, Gastaldon F, Proglio M, Brocca A, Ronco C. Brief review and a clinical case of hemolytic uremic syndrome associated with interferon beta treatment. Blood Purif 2017; 43(1-3): 136-43.
55. Orvain C, Augusto JF, Besson V, Marc G, Coppo P, Subra JF, et al. Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. Int Urol Nephrol 2014; 46(1): 239-42.
56. Larochelle C, Grand'maison F, Bernier GP, Latour M, Cailhier JF, Prat A. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon beta. Mult Scler 2014; 20(13): 1783-7.
57. Azkune C, I, Sanchez Menoyo JL, Ruiz OJ, Garcia Monco JC, Etxeguren U, I. Case report of thrombotic microangiopathy associated with subcutaneous interferon beta-1a: an emerging complication? Neurologia 2016; 31(7): 508-9.
58. Gerischer LM, Siebert E, Janke O, Jungehuelsing GJ, Ruprecht K. Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report. Mult Scler Relat Disord 2016; 10: 63-5.
59. Vosoughi R, Marriott JJ. Thrombotic microangiopathy in Interferon Beta treated multiple sclerosis patients: Review of literature and report of two new cases. Mult Scler Relat Disord 2014; 3(3): 321-5.
60. Sahraian MA, Eshaghi A. Concomitant multiple sclerosis and idiopathic thrombocytopenic purpura. Eur J Neurol 2010; 17(8): e62-e63.
61. Wallbach M, Grone HJ, Kitze B, Muller GA, Koziolek MJ. Nephrotic syndrome in a multiple sclerosis patient receiving long-term interferon beta therapy. Am J Kidney Dis 2013; 61(5): 786-9.
62. Markowitz CE. Interferon-beta: Mechanism of action and dosing issues. Neurology 2007; 68(24 Suppl 4): S8-11.
63. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010; 74(Suppl 1): S17-S24.
64. Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, et al. Interleukin 17F level and interferon beta response in patients with multiple sclerosis. JAMA Neurol 2013; 70(8):1017-21.
65. Okada K, Kuroda E, Yoshida Y, Yamashita U, Suzumura A, Tsuji S. Effects of interferon-β on the cytokine production of astrocytes. J Neuroimmunol 2005; 159(1): 48-54.
66. Pilling D, Akbar AN, Girdlestone J, Orteu CH, Borthwick NJ, Amft N, et al. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. Eur J Immunol 1999; 29(3): 1041-50.
67. Tak PP. IFN-beta in rheumatoid arthritis. Front Biosci 2004; 9: 3242-7.
68. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92(1-2): 113-21.
69. Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006; 176(11): 7119-29.
70. Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol 2011; 235(1-2): 9-17.
71. Basile E, Gibbs E, Aziz T, Oger J. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol 2006; 177(1-2): 161-6.
72. Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven-Kreitman R, et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001; 115(1-2): 152-60.
73. Teitelbaum D, Brenner T, Abramsky O, Aharoni R, Sela M, Arnon R. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003; 9(6): 592-9.
74. Sand KL, Knudsen E, Rolin J, Al-Falahi Y, Maghazachi AA. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci 2009; 66(8): 1446-56.
75. Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, et al. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler 2015; 21(3): 282-93.
76. Baldo BA, Pham NH. Drug allergy: Clinical aspects, diagnosis, mechanisms, structure-activity relationships. New York, NY: Springer; 2013. P. 15-35.
77. Corominas M, Gastaminza G, Lobera T. Hypersensitivity reactions to biological drugs. J Investig Allergol Clin Immunol 2014; 24(4): 212-25.
78. Cohen BA, Oger J, Gagnon A, Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 2008; 275(1-2): 7-17.
79. Zhang M, Chan CC, Vistica B, Hung V,Wiggert B, Gery I. Copolymer 1 inhibits experimental autoimmune uveoretinitis. J Neuroimmunol 2000; 103(2): 189-94.
80. Aharoni R, Kayhan B, Brenner O, Domev H, Labunskay G, Arnon R. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J Pharmacol Exp Ther 2006; 318(1): 68-78.
81. Aharoni R, Sonego H, Brenner O, Eilam
R, Arnon R. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells. Immunol Lett 2007; 112(2): 110-9.
82. Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 inhibits manifestations of graft rejection. Transplantation 2001; 72(4): 598-605.
83. Cui G, Zhang Y, Gong Z, Zhang JZ, Zang YQ. Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes. Cell Res 2009; 19(5): 574-83.
84. Borel P, Benkhoucha M, Weber MS, Zamvil SS, Santiago-Raber ML, Lalive PH. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model. Int Immunol 2008; 20(10): 1313-9.
Published
2018-07-05
How to Cite
1.
Baghbanian SM, Sahraian MA. Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis. IJNL. 17(3):129-36.
Section
Review Article(s)